Novel polypeptides related to b-type natriuretic peptides and methods of their identification and use
AssigneePronota N.V.
InventorsKoen Kas, Robin Tuytten, Koen De Cremer, Griet Vanpoucke
Life of this patent
Estimating the term…
Abstract
The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis.
Claims42
1-51. (canceled)
An isolated fragment of pro-B-type natriuretic peptide (proBNP) or amino terminal pro-B-type natriuretic peptide (NTproBNP) selected from:
- proBNP 3-108, 4-108 and 7-108, NTproBNP 3-76, 4-76 and 7-76, or a C-terminally truncated form of any one thereof.
A method for establishing a healthy reference or a disease reference for the presence and/or quantity of one or more fragments of proBNP, comprising:
- (a) assaying proBNP in:
- (aa) a sample from one or more subjects not having acute heart failure (AHF), chronic heart failure (CHF) or sepsis, or
- (ab) a sample from one or more subjects having AHF, CHF or sepsis,
- comprising specifically measuring the presence and/or quantity in said sample (aa) or (ab) of one or more fragments of proBNP selected from proBNP 3-108, 4-108 and 7-108 and C-terminally truncated forms thereof;
- (b) storing the presence and/or quantity of the respective fragments of proBNP and C-terminally truncated forms thereof,
- (ba) as measured in (aa) as a healthy reference or a healthy reference profile, or
- (bb) as measured in (ab) as a disease reference or a disease reference profile.
A method for establishing a healthy reference or a disease reference for the presence and/or quantity of one or more fragments of NTproBNP, comprising:
- (a) assaying NTproBNP in:
- (aa) a sample from one or more subjects not having AHF, CHF or sepsis, or
- (ab) a sample from one or more subjects having AHF, CHF or sepsis,
- comprising specifically measuring the presence and/or quantity in said sample (aa) or (ab) of one or more fragments of NTproBNP selected from NTproBNP 3-76, 4-76 and 7-76 and C-terminally truncated forms thereof;
- (b) storing the presence and/or quantity of the respective fragments of NTproBNP and C-terminally truncated forms thereof
- (ba) as measured in (aa) as a healthy reference or a healthy reference profile, or
- (bb) as measured in (ab) as a disease reference or a disease reference profile.
A method for predicting, diagnosing or prognosing recovery of sepsis or heart failure in a subject, comprising;
- a) the measurement of one or more of the NTproBNP fragments 3-76 or 4-76, or BNP fragments 3-108 and 4-108 or C-terminally truncated forms thereof, at a first time point,
- b) the measurement of one or more of the NTproBNP fragments 3-76 or 4-76, or BNP fragments 3-108 and 4-108 or C-terminally truncated forms thereof, at a later time point, and
- c) comparing both values,
- wherein a decrease in amount of either of the one or more fragments at the later time point as compared to the level at the first time point reflects recovery of heart failure of the patient and wherein an increase in amount of either of the one or more fragments in step b) compared to the level in step a) points towards a high risk of heart failure.
A method for prognosis, diagnosis and or prediction of sepsis or heart failure in a subject comprising;
- a) the measurement of one or more of the NTproBNP fragments 3-76 or 4-76, or BNP fragments 3-108 and 4-108 or C-terminally truncated forms thereof,
- b) comparing the amount of the measurement in step a) to the level of said fragment(s) in a healthy subject,
- wherein an increase in amount of either of the one or more fragments in the patient as compared to the healthy subject points towards a high risk of sepsis or heart failure.
A method for assessing the risk of suffering from heart failure in a subject comprising;
- a) measuring the total amount of NTproBNP in a sample, and
- b) measuring specifically the fragment 7-76 of NTproBNP or 7-108 of BNP or further N-terminal and/or C-terminally truncated forms thereof,
- c) calculating the total amount of NTproBNP in the sample minus the amount of the fragment 7-76 of NTproBNP or 7-108 of BNP or further N-terminal and/or C-terminally truncated forms thereof, and
- d) establishing the difference between the measurement in step c) from the patient and the measurement in step c) from a healthy subject,
- wherein an increase of said measurement in step c) in the patient as compared to a healthy subject indicates a high risk of suffering from heart failure and a decrease in said measurement in step c) in the patient as compared to a healthy subject indicates a low risk of suffering from heart failure.
Dependencies are inferred from the claim text.